natgillin/translations-raw huggingface dataset:
Florgane 300 mg/ml suspension for injection has been authorised for use in cattle as a hybrid of Nuflor 300 mg/ml solution for injection using the decentralised procedure (DE/V/0132/001/DC) with Germany as a reference Member State and Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Greece, Hungary, Ireland, Italy, Lithuania, Luxemburg, the Netherlands, Poland, Portugal, Romania, Slovakia, Spain and the United Kingdom as concerned Member States. 
Zdravilo Florgane 300 mg/ml suspenzija za injiciranje je bilo odobreno za uporabo pri govedu kot hibrid zdravila Nuflor 300 mg/ml raztopina za injiciranje z decentraliziranim postopkom (DE/V/0132/001/DC) z Nemčijo kot referenčno državo članico ter Avstrijo, Belgijo, Bolgarijo, Češko, Dansko, Francijo, Grčijo, Madžarsko, Irsko, Italijo, Litvo, Luksemburgom, Nizozemsko, Poljsko, Portugalsko, Romunijo, Slovaško, Španijo in Združenim kraljestvom kot zadevnimi državami članicami.
The referral procedure started on 15 May 2012. 
Napotitveni postopek se je začel 15. maja 2012.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics and package leaflet in Annex III. 
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s povzetkom glavnih značilnosti zdravila in navodilom za uporabo v Prilogi III.
Florfenicol is structurally related to thiamphenicol and has a similar pharmacological profile. 
Florfenikol je strukturno soroden tiamfenikolu in ima podoben farmakološki profil.
Potential serious risks were identified during the decentralised procedure by Denmark regarding the efficacy of the product and the potential for development of antimicrobial resistance to florfenicol. 
Med decentraliziranim postopkom je Danska ugotovila možna resna tveganja, povezana z učinkovitostjo zdravila in nevarnostjo za razvoj odpornosti mikrobov proti florfenikolu.
On 19 April 2012, the reference Member State, Germany, notified to the European Medicines Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC. 
Referenčna država članica, Nemčija, je 19. aprila 2012 obvestila Evropsko agencijo za zdravila, da skupina CMD(v) ni dosegla soglasja v zvezi z zdravilom, in zadevo napotila na CVMP skladno s členom 33(4) Direktive 2001/82/ES.
Written explanations were provided by the applicant on 11 September 2012 and 9 January 2013. 
Predlagatelj je 11. septembra 2012 in 9. januarja 2013 predložil pisna pojasnila, 5. marca 2013 pa še ustna pojasnila.
The proposed dose is 22.5 mg florfenicol per kg bodyweight given by intramuscular administration as a single injection. 
Predlagani odmerek je 22,5 mg florfenikola na kilogram telesne mase, ki se daje intramuskularno z enkratnim injiciranjem.
On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 20 February 2012. 
Ker ta vprašanja na 210. dan še vedno niso bila rešena, je bila zadeva 20. februarja 2012 v skladu s členom 33(1) Direktive 2001/82/ES napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v veterinarski medicini (CMD(v)).
The reference product was Nuflor Swine Injectable Solution 300 mg/ml (FR/V/0118/001). 
Referenčno zdravilo je bilo zdravilo Nuflor Swine 300 mg/ml raztopina za injiciranje (FR/V/0118/001).
This extension application (DE/V/0132/001/DX/001) was submitted according to the same procedure (DCP) and type of application (hybrid, according to Article 13(3) of Directive 2001/82/EC) as for the initial application for cattle, to the same Member States. 
Vloga za razširitev (DE/V/0132/001/DX/001) je bila predložena po istem postopku (DCP) in istim državam članicam kot prva vloga za govedo, šlo pa je tudi za isto vrsto vloge (hibridna, v skladu s členom 13(3) Direktive 2001/82/ES).
Florgane 300 mg/ml suspension for injection for cattle and pigs contains florfenicol as active ingredient and is intended for use in pigs for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae and Pasteurella multocida susceptible to florfenicol. 
Zdravilo Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče vsebuje zdravilno učinkovino florfenikol in je namenjeno za uporabo pri prašičih za zdravljenje akutnih izbruhov bolezni dihal, ki jih povzročajo sevi bakterij Actinobacillus pleuropneumoniae in Pasteurella multocida, občutljivi na florfenikol.
Day 60 of the CMD(v) procedure was on 19 April 2012, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP. 
Ker na 60. dan postopka, 19. aprila 2012, zadevne države članice še vedno niso dosegle soglasja v zvezi z zdravilom, je bil postopek napoten na CVMP.
Therefore, the Committee adopted by majority a positive opinion on 6 March 2013 recommending the granting of a marketing authorisation for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names. 
Odbor je zato 6. marca 2013 z večino sprejel pozitivno mnenje, v katerem je priporočil odobritev dovoljenja za promet z zdravilom Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče ter povezanimi imeni.
Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Florgane 300 mg/ml suspension for injection for cattle and pigs is positive. 
Na podlagi ocene trenutno razpoložljivih podatkov je CVMP menil, da je razmerje med tveganji in koristmi za zdravilo Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče pozitivno.
The applicant, Emdoka bvba, submitted an application for a decentralised procedure for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names. 
Predlagatelj, Emdoka bvba, je predložil vlogo za decentralizirani postopek za zdravilo Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče ter povezana imena.
This application is an extension to add pigs as a target species to the existing 300 mg florfenicol/ml suspension for injection product authorised for use in cattle. 
Pri vlogi gre za razširitev, s katero bi prašiče dodali kot novo ciljno vrsto k obstoječemu zdravilu 300 mg florfenikol/ml suspenzija za injiciranje, ki je odobreno za uporabo pri govedu.
Opinion following an Article 33(4)0F referral for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names EMA/324042/2013 
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)0F za zdravilo Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče ter povezana imena stran 2/2
Opinion following an Article 33(4)1 referral for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names 
za zdravilo Florgane 300 mg/ml suspenzija za injiciranje za govedo in prašiče ter povezana imena
It is available as tablets (300 mg/150 mg/300 mg). 
Na voljo je v obliki tablet (300 mg/150 mg/300 mg).
The recommended dose of Trizivir is one tablet twice a day. 
Priporočeni odmerek zdravila je ena tableta dvakrat na dan.
Other information about Trizivir: 
Druge informacije o zdravilu Trizivir:
No specific clinical studies have been carried out to assess the safety and effectiveness of the combined tablet. 
Posebnih kliničnih študij za ocenitev varnosti in učinkovitosti kombinirane tablete niso izvedli.
The European Commission granted a marketing authorisation valid throughout the EU for Trizivir on 28 December 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Trizivir, veljavno po vsej Evropski uniji, izdala 28. decembra 2000.
The full EPAR for Trizivir can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Trizivir je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Trizivir? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trizivir?
Trizivir reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Trizivir zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
Patients should have been taking the three active substances separately for at least six to eight weeks before switching to Trizivir. 
Bolniki morajo ločeno jemati vse tri zdravilne učinkovine vsaj šest do osem tednov, preden preidejo na zdravilo Trizivir.
All three active substances have been available in the European Union (EU) for a number of years: abacavir has been authorised as Ziagen since 1999, lamivudine has been authorised as Epivir since 1996, and zidovudine has been available in the EU since the mid-1980s. 
Vse tri zdravilne učinkovine so v Evropski uniji (EU) na voljo že vrsto let: abakavir je odobren kot zdravilo Ziagen od leta 1999, lamivudin kot zdravilo Epivir od leta 1996, zidovudin pa je v EU na voljo od sredine osemdesetih let prejšnjega stoletja.
In patients with high levels of HIV in the blood (above 100,000 copies/ml), the choice of treatment requires special consideration. 
Pri bolnikih z visoko ravnjo virusa HIV v krvi (nad 100 000 kopijami/ml) je treba ustrezno zdravljenje izbrati po skrbnem premisleku.
This document is a summary of the European Public Assessment Report (EPAR) for Trizivir. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Trizivir.
A risk management plan has been developed to ensure that Trizivir is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Trizivir je bil pripravljen načrt obvladovanja tveganj.
For more information about treatment with Trizivir, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Trizivir preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Patients will also receive an alert card summarising key safety information on hypersensitivity reactions with this medicine. 
Bolniki bodo prejeli tudi opozorilno kartico, ki povzema ključne varnostne informacije o tem zdravilu.
In the studies carried out for the development of Ziagen, the combination of the three active substances was shown to be at least as effective as the comparator combinations in keeping viral loads low. 
V študijah, ki jih je družba opravila med razvojem zdravila Ziagen, se je kombinacija treh zdravilnih učinkovin izkazala za enako učinkovito kot primerjalne kombinacije pri ohranjanju nizke ravni virusnega bremena.
Because it contains zidovudine, Trizivir must not be used by patients with low neutrophil counts (low levels of a type of white blood cell) or anaemia (low red blood cell counts). 
Ker zdravilo Trivizir vsebuje zidovudin, ga ne smejo uporabljati bolniki z nizkim številom nevtrofilcev v krvi (nizko ravnjo vrste belih krvnih celic) ali anemijo (nizkim številom rdečih krvnih celic).
The risk of hypersensitivity is higher in patients who have the HLA-B (type 5701) gene. 
Tveganje za pojav preobčutljivosti je večje pri bolnikih, ki imajo gen HLA-B (tip 5701).
The combination tablet was absorbed in the body in the same way as the separate tablets. 
Kombinirano tableto je telo absorbiralo enako kot ločene tablete.
The most common effects with Trizivir (seen in more than 1 patient in 10) are headache and nausea (feeling sick). 
Najpogostejša neželena učinka zdravila Trizivir (opažena pri več kot 1 bolniku od 10) sta glavobol in navzeja (slabost).
What benefit has Trizivir shown during the studies? 
Kakšne koristi je zdravilo Trizivir izkazalo med študijami?
Hypersensitivity reactions (allergic reactions) occur in patients taking Trizivir, usually within the first six weeks of treatment, and can be life-threatening. 
Preobčutljivostne (alergijske) reakcije se pojavijo pri približno 3 % bolnikov, ki jemljejo zdravilo Trizivir, običajno v prvih šestih tednih zdravljenja, in so lahko smrtno nevarne.
The CHMP noted that the reduction in the number of tablets that patients need to take may help patients stick to their treatment. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je ugotovil, da lahko z zmanjšanjem števila tablet, ki jih mora bolnik jemati, bolniki lažje vztrajajo pri zdravljenju.
Trizivir is used to treat adults who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Trizivir se uporablja za zdravljenje odraslih, ki so okuženi z virusom humane imunske pomanjkljivosti (HIV), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Trizivir does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo ne zdravi okužbe z virusom HIV ali aidsa, lahko pa podaljša čas do pojava okvare imunskega sistema ter razvoja okužb in bolezni, ki so povezane z aidsom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Trizivir. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Trizivir, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The company also looked at the way the combined tablet was absorbed in the body in comparison with the separate tablets. 
Raziskala je tudi, kako telo absorbira kombinirane tablete v primerjavi z ločenimi tabletami.
Patients with this gene are at an increased risk of having an allergic reaction to abacavir so they should not take Trizivir. 
Bolniki s tem genom so izpostavljeni višjemu tveganju za pojav alergijske reakcije na abakavir, zato ne smejo jemati zdravila Trizivir.
The company presented the results of studies with abacavir, lamivudine and zidovudine taken together, which were carried out during the development of Ziagen. 
Družba je predstavila rezultate študij o skupni uporabi abakavirja, lamivudina in zidovudina, ki jih je izvedla pri razvoju zdravila Ziagen.
Before prescribing Trizivir, doctors should consider the expected improved ability of the patient to stick to their treatment, the expected effectiveness of the medicine, and the risks associated with the active substances. 
Zdravniki naj zdravilo Trizivir predpišejo šele po premisleku o pričakovani izboljšani zmožnosti, da bolnik vztraja pri zdravljenju, pričakovani učinkovitosti zdravila in tveganjih, povezanih z zdravilnimi učinkovinami.
It also noted that the benefit of Trizivir has mainly been shown in patients who have had little or no previous HIV treatment and who do not have advanced disease. 
Ugotovil je tudi, da so se koristi zdravila Trizivir izkazale zlasti pri bolnikih, ki so se zaradi okužbe z virusom HIV zdravili krajši čas ali se sploh niso zdravili in pri katerih bolezen ni napredovala.
In addition, the company that markets Trizivir provides educational materials for doctors about hypersensitivity reactions with the medicine, including the need to test patients for the HLA-B (type 5701) gene and to remind patients to contact their doctor immediately if they develop symptoms suggestive of hypersensitivity. 
Poleg tega je družba, ki trži zdravilo Trizivir, pripravila izobraževalno gradivo za zdravnike o preobčutljivostnih reakcijah na zdravilo, vključno z zahtevo, da je treba pri bolnikih opraviti test za določanje prisotnosti gena HLA-B (tip 5701), bolnike pa opozarja, da se morajo, če se pojavijo simptomi, ki kažejo na možnost preobčutljivostne reakcije, nemudoma posvetovati z zdravnikom.
Overall, since certain other combination treatments could be more effective, the use of Trizivir should only be considered under special circumstances such as co-infection with tuberculosis (as other HIV treatments can interact with the medicines being taken by the patient). 
Na splošno so lahko nekatera druga kombinirana zdravljenja učinkovitejša, zato je treba o zdravljenju z zdravilom Trizivir razmišljati le v posebnih okoliščinah, na primer, kadar ima bolnik tudi tuberkulozo, saj lahko druga zdravila za zdravljenje okužbe z virusom HIV vplivajo na delovanje zdravil, ki jih bolnik že jemlje.
Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal pain (stomach ache), headache, signs of liver damage in the blood, myalgia (muscle pain), dyspnoea (difficulty breathing), cough, lethargy 
Med simptomi sta skoraj vedno povišana telesna temperatura ali izpuščaj, zelo pogosto pa tudi navzeja (slabost), bruhanje, driska, bolečine v trebuhu, glavobol, znaki obolenja jeter v krvi, mialgija (bolečine v mišicah), dispneja (oteženo dihanje), kašelj, letargija (pomanjkanje energije) in slabo počutje.
Before starting treatment with abacavir, all patients should have a test to find out if they have a gene called ‘HLA-B (type 5701)'. 
Pred začetkom zdravljenja z abakavirjem je treba pri vsakem bolniku opraviti test, s katerim zdravnik ugotovi, ali ima bolnik gen, imenovan HLA-B (tip 5701).
Trizivir must not be used in patients who have kidney failure. 
Zdravila Trizivir ne smejo uporabljati bolniki, ki imajo odpoved ledvic.
If patients need to stop taking abacavir, lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing abacavir, lamivudine or zidovudine separately. 
Če morajo bolniki zaradi težav z ledvicami, jetri ali krvjo prekiniti jemanje abakavirja, lamivudina ali zidovudina oziroma morajo spremeniti njihove odmerke, bodo morali prejemati ločena zdravila, ki vsebujejo le abakavir, lamivudin ali zidovudin.
What is the risk associated with Trizivir? 
Kakšna tveganja so povezana z zdravilom Trizivir?
The Committee decided that Trizivir's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Zaključil je, da so koristi zdravila Trizivir večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Trizivir abacavir, lamivudine and zidovudine 
Trizivir abakavir, lamivudin in zidovudin
It is used to replace treatment with the three active substances (abacavir, lamivudine and zidovudine) taken separately at doses similar to those in Trizivir. 
Uporablja se kot nadomestek za zdravljenje s tremi zdravilnimi učinkovinami (abakavirjem, lamivudinom in zidovudinom), ki se jemljejo posamično v podobnih odmerkih, kot so v zdravilu Trizivir.
Treatment with Trizivir should be started by a doctor who has experience in the management of HIV infection. 
Zdravljenje z zdravilom Trizivir lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Trizivir is a medicine that contains three active substances: abacavir, lamivudine and zidovudine. 
Trizivir je zdravilo, ki vsebuje tri zdravilne učinkovine: abakavir, lamivudin in zidovudin.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Trizivir, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
They all work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses. 
Učinkovine podobno zavirajo delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV, da lahko okuži celice ter tvori še več virusov.
All three active substances in Trizivir, abacavir, lamivudine, and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs). 
Vse tri zdravilne učinkovine v zdravilu Trivizir, abakavir, lamivudin in zidovudin, so nukleozidni zaviralci reverzne transkriptaze (NRTI-ji).
For the full list of all side effects reported with Trizivir, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Trizivir, glejte navodilo za uporabo.
Why has Trizivir been approved? 
Zakaj je bilo zdravilo Trizivir odobreno?
What is Trizivir used for? 
Za kaj se zdravilo Trizivir uporablja?
How has Trizivir been studied? 
Kako je bilo zdravilo Trizivir raziskano?
How is Trizivir used? 
Kako se zdravilo Trizivir uporablja?
What is Trizivir? 
Kaj je zdravilo Trizivir?
Treatment with Trizivir should be stopped promptly if the patient has a hypersensitivity reaction. 
Če se pri bolniku pojavijo preobčutljivostne reakcije, je treba zdravljenje z zdravilom Trizivir takoje prekiniti.
Repeatability was 97%. 
Ponovljivost je bila 97-odstotna.
If this happens, do not drive or use machines. 
Če se to zgodi, ne vozite in upravljajte strojev.
In the event of an overdose, symptomatic and supportive measures should be employed. 
V primeru prevelikega odmerjanja moramo uvesti simptomatske in podporne ukrepe.
During the test, the patient needs to stay fasted until the end of the blood sampling. 
Med preiskavo mora bolnik ostati tešč do konca vzorčenja krvi.
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1337/001 
ŠTEVILKA(ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/18/1337/001
You need to stop such treatment at least 1 month before the test. 
Takšno zdravljenje morate prekiniti vsaj 1 mesec pred preiskavo.
For oral use after reconstitution. 
Za peroralno uporabo po rekonstituciji.
Step 5 Have the patient drink the entire content of the drinking glass within 30 seconds. 
5. korak Bolnik naj popije celotno vsebino kozarca v 30 sekundah.
It is unknown whether such potential interactions may also affect QTc (see above). 
Ni znano, ali lahko takšne potencialne interakcije vplivajo tudi na interval QTc (glejte zgoraj).
It is unknown whether this may affect QTc. 
Ni znano, ali lahko to vpliva na interval QTc.
Stir the suspension gently for 2 minutes (a small amount of undissolved particles will remain giving a slightly turbid suspension). 
Nežno mešajte suspenzijo 2 minuti (zaradi majhne količine neraztopljenih delcev bo suspenzija vedno rahlo motna).
Transfer the measured amount to a drinking glass. 
Izmerjeno količino prenesite v kozarec.
Read all of this leaflet carefully before you take this medicine because it contains important information for you. 
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
It is used when your doctor thinks that you may not have enough growth hormone (adult growth hormone deficiency). 
Uporablja se, če vaš zdravnik meni, da morda nimate dovolj rastnega hormona (pomanjkanje rastnega hormona pri odraslih).
If you are a woman able to have children, you must use effective contraceptive methods to ensure you are not pregnant at the time of the test. 
Če ste ženska v rodni dobi, morate uporabljati učinkovite kontracepcijske metode, da zagotovite, da v času preiskave ne zanosite.
In case a patient should be reporting dizziness as side effect, the patient should be instructed to neither drive nor use machines. 
Če bolnik poroča o omotici kot neželenem učinku, mu je treba naročiti, naj ne vozi ali upravlja strojev.
If occurring, such changes would be timely limited and not last long. 
Če se takšne spremembe pojavijo, so kratkotrajne.
The median age was 41 years (range: 18 - 66 years) and body mass index 27.5 kg/m2 (range: 16 - 40 kg/m2). 
Mediana starosti je bila 41 let (razpon: 18-66 let), indeksa telesne mase pa 27,5 kg/m2 (razpon: 16-40 kg/m2).
The suspension should be stirred again, when some particles settle at the bottom of the container for example after the suspension is left standing for some time. 
Suspenzijo morate premešati še enkrat, ko se delci usedejo na dno posode, na primer ko suspenzijo pustite stati nekaj časa.